Overview

Efficacy of Lapaquistat Acetate Co-Administered With Current Lipid-Lowering Treatment on Blood Cholesterol Levels in Subjects With Homozygous Familial Hypercholesterolemia

Status:
Terminated
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the efficacy of lapaquistat acetate, once daily (QD), to lower cholesterol in subjects with homozygous familial hypercholesterolemia undergoing lipid-lowering treatment.
Phase:
Phase 3
Details
Lead Sponsor:
Takeda